MSH2 and neoplasm: In 498 tumours no loss for MMR gene products was observed, 14 tumours showed loss of MLH1 in combination with PMS2, 2 tumours showed loss of MSH6 of which one in combination with MSH2, and in one tumour the IHC staining was not evaluable.